Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Cyfuse Biomedical KK's operating assets for the quarter that ended in Dec. 2025 was 円539.49 Mil. Cyfuse Biomedical KK's operating liabilities for the quarter that ended in Dec. 2025 was 円196.40 Mil. Cyfuse Biomedical KK's Total Assets for the quarter that ended in Jun. 2025 was 円3,232.34 Mil. Therefore, Cyfuse Biomedical KK's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.11.
Cyfuse Biomedical KK Scaled Net Operating Assets Related Terms
Cyfuse Biomedical KK Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyfuse Biomedical KK Scaled Net Operating Assets Chart
TSE:4892 vs ZTS, UTHR: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.11 mean?
Cyfuse Biomedical KK (TSE:4892) has a Scaled Net Operating Assets of 0.11 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Cyfuse Biomedical KK and its competitors.
Is Cyfuse Biomedical KK's Scaled Net Operating Assets too high?
Cyfuse Biomedical KK's current Scaled Net Operating Assets is 0.11. Overall, Cyfuse Biomedical KK has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Scaled Net Operating Assets compare to ZTS and UTHR?
Cyfuse Biomedical KK's Scaled Net Operating Assets of 0.11 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Cyfuse Biomedical KK and its competitors. Cyfuse Biomedical KK's current Scaled Net Operating Assets is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,950.43, compared to a current price of 円556.00 — trading 71.5% below its estimated fair value. The current Scaled Net Operating Assets is 0.11. Cyfuse Biomedical KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current Scaled Net Operating Assets is 0.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円556.00 is trading 71.5% below its estimated GF Value™ of 円1,950.43.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for TSE:4892:
Scaled Net Operating Assets: 0.11
GF Value™: 円1,950.43 vs. price of 円556.00 (71.5% below fair value)
No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
53GF Score
Get the complete analysis for TSE:4892
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4892 has been successfully added to your 
